The Cancer-Bio-Santé competitive cluster answered a call for projects initiated by the French Government in the fall of 2004. Approved by the Inter-ministerial Committee on territorial planning and competitiveness on July 12, 2005, the Cancer-Bio-Santé competitive cluster encompasses the main actors in the Midi-Pyrénées region involved in the fight against cancer: clinical and medical organizations, research centers and industrial firms in a wide range of fields including food and agriculture, pharmaceuticals, biotechnologies, Science and Information technologies and micro-nanotechnologies, as well as higher education institutions and non-profit organizations. The Oncopole of Toulouse is a showcase for this expertise.
- Ambitions and goals
The Cancer Bio-Santé competitive cluster is based on a global, on-going approach to the fight against cancer through prevention, rooted in particular in diet, and by providing faster, more equitable patient treatment. By fostering synergies between higher education, research and industry and the development of pluri-disciplinary projects, the Cancer-Bio-Santé competitiveness cluster is determined to drive therapeutic innovation. This will ensure maximum benefit to patients but also create wealth (creation of companies, partnerships, patents, innovations) and employment.
- The mission of the Cancer-Bio-Santé Cluster
To foster cooperation between all actors
To speed up the discovery of new cancer drugs and treatment via:
- Public/private collaborative ventures and multidisciplinary projects
- The development of new technologies: biotechnologies, nanotechnologies
To drive a technological leap in bio-medical research.
To valorize a coherent zone in life sciences.
- Actors within the Cluster
The Cancer-Bio-Santé cluster draws on the Midi-Pyrénées region’s strengths which include the pharmaceuticals sector, food and agriculture, and biotechnologies.
In all, the cluster accounts for more than 20,000 private sector jobs including over 10,000 people working in R&D in industry and almost 9,000 people in public research.
Actors within the cluster include world giants, SMEs and start-ups.
The biomedical sector:
80 firms, 9,000 jobs, a turnover of 1.7 billion euros in 2001 and an annual growth rate of 15 to 30 %.
The biotech sector (Affichem, Avogadro, BT Pharma, Cayla-Invivogen, GTP Technology, MilleGen, Novaleads, PraXcell, Sinters, Unicare, Vectalys, etc.):
63 firms including 36 start-ups with a total of 332 jobs, a turnover of 24 million euros and 14% annual growth.
The food and health sector (Lallemand, GeniobioPlantes et Industrie, Lara Europe Analyse, Nutrition Santé, etc.):
30 firms and 1,100 jobs
The pharmaceutical industry (GSK, Laboratoires Pierre Fabre, Sanofi-Aventis …):
8,000 people with a turnover of 39 billion euros.
The info-technologies sector (IBM, Siemens, Thales …):
2,100 firms and 14,000 jobs.
Along with industrial actors, the Cancer-Bio-Santé cluster includes:
3 scientific and technological public research organizations (EPST) : CNRS, INRA and INSERM
4 Universities : Université Paul Sabatier (UPS), Université Toulouse II Le Mirail (UTM), Université des Sciences Sociales (UT1) and Institut National Polytechnique de Toulouse (INPT)
Top engineering and business schools including l’Ecole d’Ingénieurs de Purpan (EI Purpan), L’Ecole Nationale Supérieure d’Agronomie (INPT-ENSAT), L’Ecole Nationale Supérieure des Ingénieurs en Arts Chimiques Et Technologiques (INPT-ENSIACET), L’Institut National des Sciences Appliquées de Toulouse (INSAT), L’Ecole des Mines d’Albi Carmaux (EMAC) , L’École Nationale Vétérinaire de Toulouse (ENVT) and l’Ecole Supérieure de Commerce de Toulouse (ESCT).
Clinical research and healthcare organizations: CHU (The University Hospital) of Toulouse, The CHU of Limoges, ICR, private sector organizations, The Oncomip network, l’Etablissement Français du Sang Pyrénées-Méditerranée (The Regional French Blood Bank)
Local authorities and govermental institutions including La Communauté d’agglomération du Grand Toulouse and La Communauté d’agglomération de Castres-Mazamet, the Sicoval, Le conseil général du Tarn, Le Conseil Général de la Haute-Garonne, Le Conseil Régional Midi-Pyrénées and Le Conseil Régional du Limousin), CCIT, Conseil Economique et Social Régional de Midi-Pyrénées…
- Research projects
The Cancer-Bio-Santé cluster was created to bring together the talents and expertise of the different actors. 38 R&D projects involving industry, research and healthcare organizations have been approved by the cluster. These projects are grouped under four central themes:
Theme one: Prevention : food safety, food epidemiology, photo-induced cancers
This theme targets prevention markets: the economic impact of the disease beyond medical practice and/or drug treatment
Theme two:Molecules of therapeutic interest: pharmacological targets, drug candidates, diagnostic and pronostic markers.
This theme targets a fundamental requirement of the bio-pharmaceutical industry: the discovery of new mechanisms and active principles
Theme three: technological innovations, medical technology and imaging
This theme focuses on removing technological obstacles by drawing on different disciplines (White or Industrial biotechnologies, convergence between Info-nano-biotechnologies, etc.)
Theme four:Social health issues
This theme focuses on approving biomedical tools and equipment useful for reentry into society or social reintegration and at-home care
Four projects have been approved by the French Government which has invested 3 M€. The projects are driven by Pierre Fabre with the Inserm, the CNRS, and Toulouse-based biotech firms including GTP Technology and Vectalys, MilleGen, Cayla-Invivogen, companies in Limoges.
The cluster is governed by its own non-profit organization (l’Association Cancer-Bio-Santé created in October, 2005) including a 33 member board of directors whose role is to optimize the industrial, research and educational actions of the cluster and generally ensure that the structure operates effectively.
President : Pierre Montoriol (Président HEMODIA)
1st Vice-president : Jean Daydé (EI Purpan – PA3S)
2nd Vice-president : Jean-Jacques ROMATET (Director of CHU de Toulouse)
3rd Vice-president : Xavier TABARY (Director of Sanofi-aventis)
Treasurer : Vincent Sibaud (Laboratoires Pierre Fabre)
General Secretary : Marielle Gaudois (President of Biomedical Alliance)
Permanents de l’Association :
Managing Director : Jean-Pierre Saintouil
Project manager : Laetitia Nots
Project followup/quality manager : Leila Ameur
International activity manager : Céline Bedja
Assistant : Monique Arsicaud
Accountant : Christian Luu
INNABIOSANTE is a national research foundation and a state-approved public interest organization (decree of May 5th, 2006). The Foundation was created under the aegis of the national program to finance research and innovation.
Drawing on the vast regional research and innovation potential, the INNABIOSANTE Foundation, presided over by Philippe Douste Blazy, is devoted to financing ambitious research programs and promoting economic development in the health field and in particular in the fight against cancer.
Fostering a unique combination of key technologies including Infotechnologies, Nanotechnologies, Biotechnologies and radiotherapy and imaging techniques applied to the Health field, the INNABIOSANTE Foundation supports high level research in the Health field.
Research projects financed by the INNABIOSANTE Foundation
Jean-Louis SEGURA, Director of the Foundation
"Under the aegis of the two first ‘Fight against Cancer” call for projects, the INNABIOSANTE Foundation has set up a process to select highly inter-disciplinary research projects. Accordingly, nine projects have been selected, each of which incorporates new advanced technologies for the benefit of the health field in general and in particular in terms of cancer diagnostics.
Driven by teams from the major national and regional research institutes, the collaborative projects will allow important advances in the coming years for better diagnosis of cancer and improved therapies that more adapted to each patient’s needs.”
Projet NANO-ONCOLOGIE : Overseen by teams from the INSA of Toulouse, along with laboratories from the CNRS, the INSERM, University Paul Sabatier, the Institut Claudius Regaud, and the young innovative firm, NANOMEPS, this research project aims to produce magnetic core, iron nanoparticles for IRM imagery used in medical oncology for hyperthermal therapy.
Projet ONCOMATE : Run by teams from the LAAS-CNRS, the l’INSA in Toulouse, Université Paul Sabatier and l’Institut Claudius Regaud along with the young, innovative firm, INNOPSYS, this project focuses on developing the means to detect and dose dysfunctional proteins that indicate certain forms of cancer. In particular, the project uses the olfactory system principle thanks to nanometric chips.
Research projects financed by the INNABIOSANTE Foundation will be evaluated by independent international experts under the supervision of the Scientific Board of the Foundation presided over by Alain COSTE.
An open-doors day will be held once a year to present the projects to the general public. Project teams will present how the projects are being carried out, along with the main advances achieved and results obtained to international experts invited to attend the event.
1. The INNABIOSANTE Foundation and the Centre Pierre POTIER-ITAV
In addition, the INNABIOSANTE Foundation has a special partnership with l’Institut des Technologies Avancées en sciences du Vivant (ITAV – the Institute of Advanced Technologies in Life Sciences), housed since November 2009 in the Pierre POTIER Center.
The Foundation, which helped finance the first six ITAV projects from 2007 to 2009, is actively involved in « promotion and valorization » of the ITAV, in collaboration with the main public research organizations including the: C.N.R.S, l’INSA de Toulouse, l’Université Paul Sabatier and the regional local authorities : le Conseil Général de Haute-Garonne, le Conseil Régional Midi-Pyrénées, le Grand Toulouse.
Today, the team of Bernard DUCOMMUN, head of the ONCOSPIM project financed by the INNABIOSANTE foundation, is developing a 3D imagery system at the Pierre POTIER-ITAV Center.
ONCOSPIM includes researchers from the University Hospital Center of Toulouse, the INSERM and the Paul SABATIER University who are working to provide a solution to therapeutic failure and to enable a personalized prediction of response to pancreatic cancer treatment.
The INNABIOSANTE Foundation will soon launch a call for projects to accommodate a team of excellence within the Pierre POTIER-ITAV center, thereby confirming the Institute’s role in fostering innovation.
2. The INNABIOSANTE Foundation on an international level
A cooperative agreement was signed in Rabat, Morocco, by Latifa ELABIDA, General Secretary of the Association Lalla Salma de lutte contre le Cancer, and Philippe DOUSTE BLAZY, in the presence of his Royal Highness, Lalla SALMA, November 22, 2008.
This agreement was the basis for French-Moroccan cooperation between doctors and researchers in the following fields:
- Creation of a tumor library for research in biology and oncology in Morocco
- Training radiologists and physicians in the field of oncology
3. Making a donation to the INNABIOSANTE Foundation
The INNABIOSANTE foundation, a state-approved public interest organization as of May 5th, 2006, in keeping with its public interest and non-profit character, contributes to the development of cancer research in the region.
If you would like to help achieve advances in cancer research and healthcare in our region, please support the INNABIOSANTE foundation by making a donation or legacy, or signing up for life insurance. In doing so, you will benefit from fiscal advantages (66% tax deduction for individuals and 75% for an ISF).
For more information: www.innabiosante.fr
Hôpital La Grave
31 059 Toulouse cedex 9
Tel : 33 – 5 61 12 38 56
Fax : 33 – 5 61 12 38 47
President : Philippe DOUSTE-BLAZY
President of the Scientific Board : Alain COSTES
Director : Jean Louis SEGURA
With nearly 19,000 people (researchers, engineers, technicians, and administrative staff) including 10,500 researchers working in R&D, the Midi-Pyrénées region is the number four region in France in terms of scientific potential after l’Ile de France, Rhônes-Alpes and Provence Côte d’Azur. It is also number four in terms of R&D spending, and if one takes into account the amount of R&D spending relative to the economic weight of the region (GDP), it is number one ahead of l’Ile de France.
Public research organizations include :
12 Engineering schools, many of which are directly linked to the ONCOPOLE of Toulouse : Ecole d’Ingénieurs de Purpan (EI Purpan), Ecole Nationale supérieure d’Agronomie (INPT-ENSAT), Ecole Nationale Supérieure des Ingénieurs en Arts Chimiques Et Technologiques (INPT-ENSIACET), Institut National des Sciences Appliquées de Toulouse (INSAT), Ecole des Mines d’Albi Carmaux (EMAC), Ecole Nationale Vétérinaire de Toulouse (ENVT).
- Public research potential in the fight against cancer :
Public research organizations working on cancer related themes include :
50 public laboratories focused on health issues
20 public laboratories focused on food and agriculture to which must be added laboratories specialized in engineering (information technology, micro and nano electronics, chemical engineering…) and biotechnologies.
In all some 9000 people working in public research have either a direct link to the ONCOPOLE of Toulouse or an interface within the framework of multi-disciplinary activities which are the core of this project. The ITAV is an excellent example of the latter.
Toulouse’s higher education institutions: multiple assets
Home to nearly 110,000 students, Toulouse is the second largest university city in France after Paris.
In addition, the region’s higher education institutions have recently been streamlined and reorganized to improve international visibility and make program offerings more user-friendly to students. This more effective organization has also been designed to encourage the development of pluri-disciplinary programs, which are at the heart of Cancer-related fields.
Some 300 research professors participate in Life Sciences programs. Training is based on close cooperation between university establishments and public research organizations including the CNRS, the INRA and the INSERM, via:
- Life Sciences Masters programs
- A "Biology, Health Biotechnoelogies"Doctoral school
This program features:
- 690 research professors and researchers
- 421 doctoral students
- 70 theses defended per year on average
- 18 teams working on cancer-related issues.
Within the framework of the ONCOPOLE of Toulouse, a special effort will be made to provide continuous training to meet the needs of all actors on the site.
Many partnerships have already been developed under the aegis of theme-based collaborative projects, joint laboratories (UMR and UMS CNRS-Pierre Fabre) and regional, national and European networks. These partnerships are in a wide spectrum of fields (clinical, screening technologies, bio-production tools, molecular modeling, etc.) via both educational institutions and research organizations. The fact that industrial partners have access to the site’s technological platforms (while obviously respecting industrial property and confidentiality issues) helps guarantee lasting partnerships.
- ONCOMIP : the regional cancerology network in Midi-Pyrénées
In 1999, the region created a cancerology network, ONCOMIP, which coordinates links between cancer field actors working in the region and is devoted to promoting Clinical cancer research throughout the region.
- Le Cancéropôle Grand Sud-ouest
Le Cancéropôle Grand Sud-Ouest (GSO) is one of seven « Cancéropoles » (Cancer centers) identified at the national level by the National Cancer Institute (INCa) under the aegis of the Governmental Cancer Plan.
Using an inter-regional and multi-disciplinary approach, the objective of this organization is to mobilize the nearly 300 teams of researchers and clinical practitioners working in the cancer field in the entire territory: Aquitaine in Bordeaux, Limousin in Limoges, Languedoc-Roussillon in Montpellier and Nîmes and Midi-Pyrénées in Toulouse.
In all, more than 1500 people in research laboratories (Inserm, CNRS, the Universities), clinical services (6 University Hospitals and 3 Centers devoted to fighting Cancer), pharmaceutical laboratories (Pierre Fabre-Médicaments, Sanofi-Aventis) as well as many biotech companies are working to pool expertise and equipment in the fight against cancer to better satisfy patient needs.
Globally, the aim is to promote a research network based on teams with complementary expertise working in different sites of the Cancéropôle GSO. This new dynamic, created and supported by the Government Cancer Plan, aims to strengthen inter-regional cooperation and make the latter more competitive at the international level, while better satisfying patient needs. The main goal of all projects encompassed within the scope of the organization is to provide better cancer treatment with the discovery of new therapeutic targets likely to result in innovative therapies. Most Toulouse teams in the Cancéropôle Grand Sud-Ouest will soon be based at the Langlade campus.
- Le Centre National de la Recherche Scientifique (The National Center for Scientific Research) CNRS :
The National Center for Scientific Research (C.N.R.S) is a fundamental public research organization (a scientific and technological public organization), under the authority of the Ministry of Research. The CNRS creates knowledge and puts it to use for society. The main multi-disciplinary research organization in France, the CNRS encompasses research in very diverse scientific, technological and social fields. It covers the full range of scientific fields whether in mathematics, physics, information and communication sciences and technologies, nuclear physics and high energies, planetary sciences, chemistry, the life sciences, human and social sciences, environmental sciences, and engineering sciences. In the Midi-Pyrénées, the CNRS is present in all areas of knowledge and at the interfaces between disciplines, in particular in the life sciences. At the first inter-ministerial call for projects in 2005, the Midi-Pyrénées region earned certification for two centers of expertise:
- Aeronautics, Space and Embedded Systems : Aerospace Valley - Midi-Pyrénées - Aquitaine, with a global vocation.
- Cancer-Bio-Santé (C.B.S or Cancer Bio Health) - Limousin - Midi-Pyrénées, with a national vocation.
The CNRS has a role in the governance of the two centers at the board of director level.
Several CNRS scientific teams in the Midi-Pyrénées work in the cancer field and certain are directly involved in the ONCOPOLE of Toulouse :
Le Centre de Ressources Technologiques pour Recherches Interdisciplinaires autour du Vivant (CRT-RIV – The Technological Resource Center for Life Sciences-related inter-disciplinary research) (UMS CNRS/UPS/INSA)
The aim of the UMS is to bring together and oversee ITAV-approved technological platforms (Advanced Institute of life sciences) in close collaboration with partner laboratories.
- Nanobiotechnologies (LAAS-UPR 8001),
- Chemistry/biology interface, synthetic chemistry (partenaire SCPMIB),
- In vivo imaging (IPBS-UMR 5089),
- Bioinformatics, modelization (CEEI Théogone)
These platforms include high technology equipment. They are innovative and favor the emergence of inter-disciplinary research. They provide complementary equipment to laboratories and are open to the entire scientific community:
- To support projects encompassed by the ITAV
- To accommodate external public and private users (service platforms).
The ITAV is an inter-disciplinary research project center dedicated to innovation and entrepreneurial transfer. The research themes supported by the UMS platforms are defined by the content s of the ITAV call for projects in the field of bio-nano-technologies applied to health.
Joint CNRS/Pierre Fabre teams will move into the Pierre Fabre building in the fall
Finally, the C.N.R.S has helped finance the CPER of the C.R.C.T, a public research building overseen by the INSERM.